ALAMEDA, Calif.--(BUSINESS WIRE)--Celera (NYSE:CRA), an Applera Corporation business, today announced it has completed the acquisition of substantially all of the assets of Atria Genetics, Inc. for approximately $33 million in cash. South San Francisco-based Atria has a line of human leukocyte antigen (HLA) testing products that are used for identifying potential donors in the matching process for bone marrow transplantation. Atria was a privately held company with 13 employees, all of whom are expected to be integrated into Celera.
